Highlights GAAP total revenue of $1.15 billion and $4.39 billion for the fourth quarter and year ended December 31, 2018, respectively. Adjusted service revenue under ASC 606 of $1.15 billion and $4.40 billion for the fourth quarter and year ended December 31, 2018, respectively.
MORRISVILLE, N.C. , March 14, 2019 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), will release its fourth quarter and year end 2018
MORRISVILLE, N.C. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH) announced today that it has delayed its previously announced earnings release and conference call to allow additional time to complete its Form 10-K for the year ended December 31, 2018 .
MORRISVILLE, N.C. , Jan. 25, 2019 (GLOBE NEWSWIRE) -- Syneos Health TM (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), will release its fourth quarter and year end 2018
MORRISVILLE, N.C. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of Paul Colvin as President, Clinical Solutions. Colvin joins Syneos Health from Pharmaceutical Product
Company to Release New Survey Findings from C-Suite Leaders on Commercial Spend and Planning and Essentials for a Successful Launch MORRISVILLE, N.C. , Jan. 04, 2019 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will share new
